These findings could support the hypothesis that myostatin contributes to greater inflammatory processes; however, due to the cross-sectional nature of these studies, it is impossible to attribute causality, so more longitudinal studies are necessary to evaluate whether the control of myostatin levels in patients with RA could also benefit the patient’s cardiovascular health. This evidence concerns the gene MSTN and rheumatoid arthritis.